Progress in molecular-based management of differentiated thyroid cancer

Article

关键词: FINE-NEEDLE-ASPIRATION;    2ND PRIMARY MALIGNANCIES;    BRAF V600E MUTATION;    LONG-TERM SURVEILLANCE;    LYMPH-NODE METASTASIS;    PHASE-II TRIAL;    RADIOACTIVE IODINE;    BRAF(V600E) MUTATION;    GENETIC ALTERATIONS;    RADIOIODINE UPTAKE;   

DOI  :  10.1016/S0140-6736(13)60109-9

来源: SCIE

【 摘 要 】

Substantial developments have occurred in the past 5-10 years in clinical translational research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new gene expression classifier, are outstanding examples that have improved diagnosis of thyroid nodules. BRAF mutation is a prognostic genetic marker that has improved risk stratification and hence tailored management of patients with thyroid cancer, including those with conventionally low risks. Novel molecular-targeted treatments hold great promise for radioiodine-refractory and surgically inoperable thyroid cancers as shown in clinical trials; such treatments are likely to become a component of the standard treatment regimen for patients with thyroid cancer in the near future. These novel molecular-based management strategies for thyroid nodules and thyroid cancer are the most exciting developments in this unprecedented era of molecular thyroid-cancer medicine.

【 授权许可】

Free